Summary of Akari Therapeutics Update Call Company Overview - **Company**: Akari Therapeutics - **Ticker**: AKTX (listed on NASDAQ) [5] Key Developments - **New Patent Filing**: Akari announced the filing of a key new patent and unveiled its second ADC pipeline candidate, AKTX-102, targeting CEACAM5 expressing solid tumors [5][20] - **Lead Program**: The lead ADC, AKTX-101, is progressing towards IND (Investigational New Drug) submission and first-in-human clinical studies [13][20] Core Insights - **ADC Pipeline Expansion**: The introduction of AKTX-102 demonstrates the scalability of Akari's PH1-powered ADC platform, indicating the potential to create a library of differentiated ADC molecules [8][9] - **Unique Targeting Approach**: CEACAM5 is a challenging oncology target due to its shedding into the blood, complicating effective targeting. Akari has developed a novel antibody design to address these challenges, providing a competitive advantage [11][12] - **Focus on Lead Program**: AKTX-101 remains the primary focus, with IND-enabling activities underway, targeting a filing by the end of 2026 [13][20] Intellectual Property (IP) Strategy - **Growing IP Portfolio**: The recent patent filing expands Akari's IP estate, which includes unique antibody designs and modes of action for their payloads. This is expected to support long-term value creation and potential partnerships [17][19] - **Previous Patents**: Akari filed three patents last year, including protections for the composition of matter for their RNA splicing targeting payload, PH1 [19] Future Milestones - **Key Milestones**: - Targeting IND or CTA filing by the end of 2026 to initiate a first-in-human phase 1 study [20][21] - Initial clinical data readout expected within 18 months, focusing on safety and potential efficacy [21][22] - **Ongoing Development**: Akari will continue to present compelling preclinical data and engage with regulators throughout the year [22] Conclusion - Akari Therapeutics is positioned for significant developments in 2026, with a focus on advancing its ADC pipeline and expanding its intellectual property portfolio, which could lead to valuable partnerships and long-term growth [23]